17.10.2012 - The dreams of Wilex CEO Olaf Wilhelm to bring a drug to the market are destroyed. The company's most advanced compound has failed in Phase III.
On Tuesday evening, the Munich-based antibody developer reported results of a comprehensive Phase III study testing an anti-CA-IX antibody in the adjuvant treatment of renal cancer after surgery. The analysis showed no improvement in median disease free survival (approximately 72 months) following treatment with Rencarex compared with placebo. The Independent Data Monitoring Committee has recommended to terminate the Phase III ARISER trial which was started as long ago as in June 2004.
Originally, the company planned to announce the results in 2008. However, the number of adverse events did not come in as planned. Professor Seppo Pyrhoenen, Chairman of the ARISER IDMC, said: "I have over 30 years experience in treating patients with kidney cancer and applaud this study for being well balanced, controlled and very well conducted. This is probably the most comprehensive study in the adjuvant setting conducted in the past 20 years."
Wilex is also conducting Phase II trials with Mesupron in pancreatic and breast cancer and developing a diagnostic based on a radioactively labelled version of Rencarex in Phase III. At the Frankfurt stock exchange, Wilex shares fell more than 60%. The biggest shareholder is SAP founder Dietmar Hopp.
26.05.2016 BigDNA relaunches as Iceni Pharmaceuticals with the aim to develop repurposed and reformulated cancer therapies. First order of business: repurpose Merck Serono’s cilengitide as a multiple myeloma treatment.
24.05.2016 One of the pioneering companies developing pharmaceuticals and diagnostics based on the gut microbiome, Enterome Bioscience, has raised €14.5m in a Series C financing round. Among the investors were Seventure and Lundbeckfond as well as Nestlé.
20.05.2016 The long awaited global review on antimicrobial resistance by economist Lord Jim O’Neill has been published. It sets out an action plan to defeat superbugs with a huge awareness campaign and rapid diagnostics to be used before antibiotics are prescribed.
18.05.2016 Bayer is deepening its involvement in CRISPR with a licensing agreement for genome editing patents. Irish partner ERS Genomics holds the rights to the CRISPR/Cas9 tech from Emmanuelle Charpentier, one of the inventors.
11.05.2016 Newly spun out company OxStem has raised £16.9m (€21.5m) to develop regenerative meds for the treatment of age-related disease. It is the largest financing for an Oxford spin-out – or any UK academic spin-out – to date.
09.05.2016 Swiss Genentech partner AC Immune has raised CHF42.7m (€38.6m) in order to advance its therapeutic and diagnostic product pipeline in Alzheimer’s disease. The news follows a recently announced R&D collaboration with Biogen.
04.05.2016 Barcelona-based epigenetics expert Oryzon Genomics has closed a debt funding round of €10.5m, bringing the total money raised since last year to €27m. The funds will serve to advance the company’s two LSD1 inhibitors in cancer and neurodegeneration.
03.05.2016 Ipsen is strengthening its ties to long-time development partner Oncodesign, a Dijon-based cancer treatment biotech. The French pharma is handing over the pre-clinical pharmacology for its oncology research programmes to Oncodesign.